Sihuan Pharmaceuticals hopes to raise up to $741m through its Hong Kong public offering, according to Reuters.
China’s largest cardio-cerebral vascular drug manufacturer is selling 1.25 billion new shares, equivalent to 25% of its share capital.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company has also signed up six investors, including CCB International and China Life Insurance, for a combined $190m worth of shares.
Investment in Chinese medical firms has grown recently, a result of Beijing’s promises to create a national healthcare system coupled with the sector’s strong market momentum and ability to produce a quick profit for investors.
Sihuan markets its products, including cardio-cerebral vascular, metabolic and nervous system medications, through a network covering approximately 10,000 hospitals and medical institutions across China.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
